In clinical observations, patients with higher baseline CD4+ counts exhibited improved immune recovery following Esmolol treatment, while those with severe lymphopenia showed no clear benefit, suggesting that the efficacy of β1AR blockade may vary based on pre-existing immune function. Here, ADRB1 is linked to lymphopenia.